Evolus Reports Third Quarter 2024 Results
Evolus, Inc. (EOLS)
Last evolus, inc. earnings: 2/25 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
us.evolis.com/investor-relations
Company Research
Source: Business Wire
Total Net Revenue of $61.1 Million for Q3 2024, Up 22% from Q3 2023; Year-To-Date Growth of 33%Received Approval for Estyme® Injectable Hyaluronic Acid (HA) Gels in the European Union; Experience Program to Launch Immediately with Full Launch Expected in the Second Half of 2025Premarket Approval (PMA) Application for Evolysse™ Form and Evolysse™ Smooth Injectable HA Gels Currently Under Review by the U.S. Food and Drug Administration (FDA) with Approval and Launch Expected by September 2025Narrows Full-Year 2024 Net Revenue Guidance to $260 Million to $266 Million, Representing Year-Over-Year Growth of 29% to 32%Reaffirms Non-GAAP Profitability1 in Q4 2024 and Full Year 2025Remains on Track to Achieve Projected Total Net Revenue Goal of At Least $700 Million and Operating Margin of At Least 20% by 2028 NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported f
Show less
Read more
Impact Snapshot
Event Time:
EOLS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EOLS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EOLS alerts
High impacting Evolus, Inc. news events
Weekly update
A roundup of the hottest topics
EOLS
News
- Botox Competitor Jeuveau Launches A $49-A-Month Membership [Forbes]Forbes
- Here's Why Evolus (EOLS) Could be Great Choice for a Bottom Fisher [Yahoo! Finance]Yahoo! Finance
- Down -29.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Evolus (EOLS) [Yahoo! Finance]Yahoo! Finance
- Earnings Update: Evolus, Inc. (NASDAQ:EOLS) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts [Yahoo! Finance]Yahoo! Finance
- Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.MarketBeat
EOLS
Earnings
- 11/6/24 - Miss
EOLS
Sec Filings
- 11/14/24 - Form SCHEDULE
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- EOLS's page on the SEC website